No Cover Image

Journal article 111 views 6 downloads

Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin

Amira Guirguis Orcid Logo, Arianna Giorgetti Orcid Logo, Jegak Seo Orcid Logo, John Martin Corkery Orcid Logo, Fabrizio Schifano Orcid Logo

Brain Sciences, Volume: 16, Issue: 6, Start page: 602

Swansea University Author: Amira Guirguis Orcid Logo

  • 71948.VOR.pdf

    PDF | Version of Record

    © 2026 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

    Download (283.15KB)

Check full text

DOI (Published version): 10.3390/brainsci16060602

Abstract

Methamphetamine presents a significant scientific and legal challenge for sentencing because, although it is a Class A drug in England and Wales, it is not assigned explicit indicative quantity thresholds within the principal Sentencing Council guideline. This review provides a comparative expert sy...

Full description

Published in: Brain Sciences
ISSN: 2076-3425
Published: MDPI AG 2026
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa71948
first_indexed 2026-05-19T08:01:57Z
last_indexed 2026-06-10T08:54:03Z
id cronfa71948
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2026-06-09T12:47:32.6517036</datestamp><bib-version>v2</bib-version><id>71948</id><entry>2026-05-19</entry><title>Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin</title><swanseaauthors><author><sid>b49270b9a0d580cf4f31f9a1b6c93f87</sid><ORCID>0000-0001-8255-0660</ORCID><firstname>Amira</firstname><surname>Guirguis</surname><name>Amira Guirguis</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2026-05-19</date><deptcode>MEDS</deptcode><abstract>Methamphetamine presents a significant scientific and legal challenge for sentencing because, although it is a Class A drug in England and Wales, it is not assigned explicit indicative quantity thresholds within the principal Sentencing Council guideline. This review provides a comparative expert synthesis of methamphetamine in relation to amphetamine, cocaine and heroin, with particular emphasis on pharmacodynamics, pharmacokinetics, route-specific harms, fatal toxicity indicators and broader patterns of individual-harm profiles. The analysis draws on human laboratory studies, neuroimaging, pharmacokinetic investigations, toxicological literature, drug-related mortality data and policy sources to assess where methamphetamine most appropriately sits within a harm-based sentencing framework. The evidence indicates that methamphetamine is pharmacologically closest to amphetamine, sharing core monoaminergic mechanisms of transporter-mediated neurotransmitter release and vesicular disruption, but differing across several pharmacokinetic and toxicity-related parameters. Compared with amphetamine, methamphetamine shows greater lipid solubility, more efficient central nervous system penetration, longer persistence, and exposure that may, under common high-intensity routes of use, be associated with higher risk of neuropsychiatric, cardiovascular and cerebrovascular harms. Smoked methamphetamine in particular achieves high systemic bioavailability and rapid onset, creating a pattern of exposure more severe than conventional amphetamine preparations and, in some practical respects, closer to high-intensity stimulant models such as crack cocaine. Contemporary evidence further indicates that methamphetamine is associated with higher fatal toxicity than amphetamine, although the magnitude of difference varies by endpoint and no single universal gram-for-gram conversion is supported or recommended. Overall, the literature does not justify treating methamphetamine as simply equivalent to amphetamine, nor does it support conflating it fully with heroin or crack cocaine. The most defensible interpretation is that amphetamine should remain the primary scientific comparator, but with upward adjustment to reflect methamphetamine&#x2019;s greater persistence and toxicity-related burden, while cocaine may serve as a secondary comparator for proportionality within the Class A sentencing framework. Taken together, the evidence supports consideration of an upward-adjusted amphetamine-based interpretation rather than an unadjusted amphetamine analogue.</abstract><type>Journal Article</type><journal>Brain Sciences</journal><volume>16</volume><journalNumber>6</journalNumber><paginationStart>602</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2076-3425</issnElectronic><keywords>methamphetamine; amphetamine; cocaine; toxicity; smoked; sentencing comparator</keywords><publishedDay>31</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2026</publishedYear><publishedDate>2026-05-31</publishedDate><doi>10.3390/brainsci16060602</doi><url/><notes>Opinion</notes><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Not Required</apcterm><funders/><projectreference/><lastEdited>2026-06-09T12:47:32.6517036</lastEdited><Created>2026-05-19T08:54:30.5462145</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>Amira</firstname><surname>Guirguis</surname><orcid>0000-0001-8255-0660</orcid><order>1</order></author><author><firstname>Arianna</firstname><surname>Giorgetti</surname><orcid>0000-0002-0441-9787</orcid><order>2</order></author><author><firstname>Jegak</firstname><surname>Seo</surname><orcid>0000-0002-7199-3041</orcid><order>3</order></author><author><firstname>John Martin</firstname><surname>Corkery</surname><orcid>0000-0002-3849-817x</orcid><order>4</order></author><author><firstname>Fabrizio</firstname><surname>Schifano</surname><orcid>0000-0002-4178-5401</orcid><order>5</order></author></authors><documents><document><filename>71948__36897__f1bc1391d8764b49846a4983c77046ff.pdf</filename><originalFilename>71948.VOR.pdf</originalFilename><uploaded>2026-06-09T12:44:51.2783570</uploaded><type>Output</type><contentLength>289941</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2026 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2026-06-09T12:47:32.6517036 v2 71948 2026-05-19 Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin b49270b9a0d580cf4f31f9a1b6c93f87 0000-0001-8255-0660 Amira Guirguis Amira Guirguis true false 2026-05-19 MEDS Methamphetamine presents a significant scientific and legal challenge for sentencing because, although it is a Class A drug in England and Wales, it is not assigned explicit indicative quantity thresholds within the principal Sentencing Council guideline. This review provides a comparative expert synthesis of methamphetamine in relation to amphetamine, cocaine and heroin, with particular emphasis on pharmacodynamics, pharmacokinetics, route-specific harms, fatal toxicity indicators and broader patterns of individual-harm profiles. The analysis draws on human laboratory studies, neuroimaging, pharmacokinetic investigations, toxicological literature, drug-related mortality data and policy sources to assess where methamphetamine most appropriately sits within a harm-based sentencing framework. The evidence indicates that methamphetamine is pharmacologically closest to amphetamine, sharing core monoaminergic mechanisms of transporter-mediated neurotransmitter release and vesicular disruption, but differing across several pharmacokinetic and toxicity-related parameters. Compared with amphetamine, methamphetamine shows greater lipid solubility, more efficient central nervous system penetration, longer persistence, and exposure that may, under common high-intensity routes of use, be associated with higher risk of neuropsychiatric, cardiovascular and cerebrovascular harms. Smoked methamphetamine in particular achieves high systemic bioavailability and rapid onset, creating a pattern of exposure more severe than conventional amphetamine preparations and, in some practical respects, closer to high-intensity stimulant models such as crack cocaine. Contemporary evidence further indicates that methamphetamine is associated with higher fatal toxicity than amphetamine, although the magnitude of difference varies by endpoint and no single universal gram-for-gram conversion is supported or recommended. Overall, the literature does not justify treating methamphetamine as simply equivalent to amphetamine, nor does it support conflating it fully with heroin or crack cocaine. The most defensible interpretation is that amphetamine should remain the primary scientific comparator, but with upward adjustment to reflect methamphetamine’s greater persistence and toxicity-related burden, while cocaine may serve as a secondary comparator for proportionality within the Class A sentencing framework. Taken together, the evidence supports consideration of an upward-adjusted amphetamine-based interpretation rather than an unadjusted amphetamine analogue. Journal Article Brain Sciences 16 6 602 MDPI AG 2076-3425 methamphetamine; amphetamine; cocaine; toxicity; smoked; sentencing comparator 31 5 2026 2026-05-31 10.3390/brainsci16060602 Opinion COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Not Required 2026-06-09T12:47:32.6517036 2026-05-19T08:54:30.5462145 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy Amira Guirguis 0000-0001-8255-0660 1 Arianna Giorgetti 0000-0002-0441-9787 2 Jegak Seo 0000-0002-7199-3041 3 John Martin Corkery 0000-0002-3849-817x 4 Fabrizio Schifano 0000-0002-4178-5401 5 71948__36897__f1bc1391d8764b49846a4983c77046ff.pdf 71948.VOR.pdf 2026-06-09T12:44:51.2783570 Output 289941 application/pdf Version of Record true © 2026 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. true eng https://creativecommons.org/licenses/by/4.0/
title Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
spellingShingle Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
Amira Guirguis
title_short Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
title_full Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
title_fullStr Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
title_full_unstemmed Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
title_sort Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin
author_id_str_mv b49270b9a0d580cf4f31f9a1b6c93f87
author_id_fullname_str_mv b49270b9a0d580cf4f31f9a1b6c93f87_***_Amira Guirguis
author Amira Guirguis
author2 Amira Guirguis
Arianna Giorgetti
Jegak Seo
John Martin Corkery
Fabrizio Schifano
format Journal article
container_title Brain Sciences
container_volume 16
container_issue 6
container_start_page 602
publishDate 2026
institution Swansea University
issn 2076-3425
doi_str_mv 10.3390/brainsci16060602
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
document_store_str 1
active_str 0
description Methamphetamine presents a significant scientific and legal challenge for sentencing because, although it is a Class A drug in England and Wales, it is not assigned explicit indicative quantity thresholds within the principal Sentencing Council guideline. This review provides a comparative expert synthesis of methamphetamine in relation to amphetamine, cocaine and heroin, with particular emphasis on pharmacodynamics, pharmacokinetics, route-specific harms, fatal toxicity indicators and broader patterns of individual-harm profiles. The analysis draws on human laboratory studies, neuroimaging, pharmacokinetic investigations, toxicological literature, drug-related mortality data and policy sources to assess where methamphetamine most appropriately sits within a harm-based sentencing framework. The evidence indicates that methamphetamine is pharmacologically closest to amphetamine, sharing core monoaminergic mechanisms of transporter-mediated neurotransmitter release and vesicular disruption, but differing across several pharmacokinetic and toxicity-related parameters. Compared with amphetamine, methamphetamine shows greater lipid solubility, more efficient central nervous system penetration, longer persistence, and exposure that may, under common high-intensity routes of use, be associated with higher risk of neuropsychiatric, cardiovascular and cerebrovascular harms. Smoked methamphetamine in particular achieves high systemic bioavailability and rapid onset, creating a pattern of exposure more severe than conventional amphetamine preparations and, in some practical respects, closer to high-intensity stimulant models such as crack cocaine. Contemporary evidence further indicates that methamphetamine is associated with higher fatal toxicity than amphetamine, although the magnitude of difference varies by endpoint and no single universal gram-for-gram conversion is supported or recommended. Overall, the literature does not justify treating methamphetamine as simply equivalent to amphetamine, nor does it support conflating it fully with heroin or crack cocaine. The most defensible interpretation is that amphetamine should remain the primary scientific comparator, but with upward adjustment to reflect methamphetamine’s greater persistence and toxicity-related burden, while cocaine may serve as a secondary comparator for proportionality within the Class A sentencing framework. Taken together, the evidence supports consideration of an upward-adjusted amphetamine-based interpretation rather than an unadjusted amphetamine analogue.
published_date 2026-05-31T06:02:37Z
_version_ 1868490874218872832
score 11.109323

Similar Items